Table 3.
Included studies reporting the risk of CV events in populations with severe obesity with NGT/T2D
| Study | Year | Country | Glycemic status | BMI (kg/m2) | Risk of | HR | Note |
|---|---|---|---|---|---|---|---|
| Edqvist et al. [59] | 2019 | Sweden | T2D (HbA1c <53 mmol/mol) | ≥ 40 | MI | 1.53 (95% CI 1.25–1.87) | Relative to no T2D |
| T2D (HbA1c 53–70 mmol/mol) | 1.97 (95% CI 1.63–2.38) | ||||||
| T2D (HbA1c <53 mmol/mol) | Hospitalization for heart failure | 5.01 (95% CI 3.93–6.39) | |||||
| T2D (HbA1c 53–70 mmol/mol) | 5.86 (95% CI 4.57–7.51) | ||||||
| Iyen et al. [61] | 2021 | UK | Not reported | Morbidly obese (average BMI 49.1) | Stroke/transient ischemic attack | 1.04 (95% CI 0.93–1.18) | Relative to overweight (BMI 25–30) |
| Mørkedal et al. [60] | 2014 | Norway | NGT | ≥ 40 | MI | 0.9 (95% CI 0.3–2.9) | Relative to BMI < 25 |
| T2D or prediabetes | 1.8 (95% CI 1.1–3.1) |
BMI body mass index, CI confidence interval, CV cardiovascular, HbA1c glycated hemoglobin, HR hazard ratio, NGT normal glucose tolerance, MI myocardial infarction, T2D type 2 diabetes